Literature DB >> 28857208

Temporal trends, clinical patterns and outcomes of NAFLD-related HCC in patients undergoing liver resection over a 20-year period.

R Pais1,2, L Fartoux1, C Goumard3, O Scatton3, D Wendum4, O Rosmorduc1, V Ratziu1,2.   

Abstract

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is an increasing cause of hepatocellular carcinoma (HCC) worldwide. NAFLD-HCC often occurs in noncirrhotic liver raising important surveillance issues. AIM: To determine the temporal trends for prevalence, clinical characteristics and outcomes of NAFLD-HCC in patients undergoing liver resection.
METHODS: Consecutive patients with histologically confirmed HCC who underwent liver resection over a 20-year period (1995-2014). NAFLD was diagnosed based on past or present exposure to obesity or diabetes without other causes of chronic liver disease.
RESULTS: A total of 323 HCC patients were included, 12% with NAFLD. From 1995-1999 to 2010-2014, the prevalence of NAFLD-HCC increased from 2.6% to 19.5%, respectively, P = .003, and followed the temporal trends in the prevalence of metabolic risk factors (28% vs 52%, P = .017), while hepatitis C-HCC decreased (from 43.6% to 19.5%, P = .003). NAFLD-HCC occurred more frequently in the absence of bridging fibrosis/cirrhosis (63% of cases, P < .001 compared to other aetiologies). Within the NAFLD group, tumour characteristics were similar between F0-F2 and F3-F4 patients, except for a higher proportion of single nodules (95% vs 54%, P < .01). A total of 53% patients had tumour recurrence and 40% died. NAFLD-HCC had similar time to recurrence and survival as HCCs of other aetiologies. Satellite nodules, tumour size, microvascular invasion and male sex but not the aetiology were independently associated with recurrence.
CONCLUSION: Non-alcoholic fatty liver disease increased substantially over the past 20 years among resectable HCCs. It is now the leading cause of HCC occuring without/or with only minimal fibrosis. NAFLD patients are older, with larger tumours while survival and recurrence rates are as severe as in other aetiologies.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  hepatocellular carcinoma; liver resection; metabolic risk factors; non-alcoholic fatty liver disease

Mesh:

Year:  2017        PMID: 28857208     DOI: 10.1111/apt.14261

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  27 in total

1.  Editorial: NAFLD-related hepatocellular carcinoma - increasing or not? With or without cirrhosis?

Authors:  M Balakrishnan; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2018-02       Impact factor: 8.171

2.  Dissociating nonalcoholic steatohepatitis from hepatocellular carcinoma in obesity.

Authors:  Stergios A Polyzos; Jannis Kountouras; Antonis Goulas; Eleni Papakonstantinou; Paraskevi Papaioannidou
Journal:  Hepatobiliary Surg Nutr       Date:  2020-02       Impact factor: 7.293

3.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Authors:  Mohammed Eslam; Shiv K Sarin; Vincent Wai-Sun Wong; Jian-Gao Fan; Takumi Kawaguchi; Sang Hoon Ahn; Ming-Hua Zheng; Gamal Shiha; Yusuf Yilmaz; Rino Gani; Shahinul Alam; Yock Young Dan; Jia-Horng Kao; Saeed Hamid; Ian Homer Cua; Wah-Kheong Chan; Diana Payawal; Soek-Siam Tan; Tawesak Tanwandee; Leon A Adams; Manoj Kumar; Masao Omata; Jacob George
Journal:  Hepatol Int       Date:  2020-10-01       Impact factor: 6.047

4.  Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.

Authors:  Fanhong Zeng; Yue Zhang; Xu Han; Min Zeng; Yi Gao; Jun Weng
Journal:  Front Immunol       Date:  2021-01-26       Impact factor: 7.561

5.  Primary Care Provider Practice Patterns and Barriers to Hepatocellular Carcinoma Surveillance.

Authors:  Okeefe L Simmons; Yuan Feng; Neehar D Parikh; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2018-07-26       Impact factor: 11.382

6.  Liver Resection for Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: a Multicenter Propensity Matching Analysis with HBV-HCC.

Authors:  Tian Yang; Lun-Yang Hu; Zhen-Li Li; Kai Liu; Han Wu; Hao Xing; Wan Yee Lau; Timothy M Pawlik; Yong-Yi Zeng; Ya-Hao Zhou; Wei-Min Gu; Hong Wang; Ting-Hao Chen; Jun Han; Chao Li; Ming-Da Wang; Meng-Chao Wu; Feng Shen
Journal:  J Gastrointest Surg       Date:  2019-01-07       Impact factor: 3.452

7.  The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study.

Authors:  Yuri Cho; Eun Ju Cho; Jeong-Ju Yoo; Young Chang; Goh Eun Chung; In Young Choi; Sang-Hyun Park; Kyungdo Han; Yoon Jun Kim; Jung-Hwan Yoon; Dong Wook Shin; Su Jong Yu
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

Review 8.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

Review 9.  Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention.

Authors:  Daniel Q Huang; Hashem B El-Serag; Rohit Loomba
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-12-21       Impact factor: 46.802

Review 10.  Hepatocellular carcinoma in non-alcoholic fatty liver disease-a review of an emerging challenge facing clinicians.

Authors:  Daniel Geh; Derek M Manas; Helen L Reeves
Journal:  Hepatobiliary Surg Nutr       Date:  2021-01       Impact factor: 8.265

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.